A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
The study will last about 24 weeks and may include up to 12 visits (follow up includes up to 3 visits).
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have chronic plaque psoriasis diagnosed for at least 6 months before to participate in the study
-Participants must have >=10% body surface area involvement
-Participants must agree to use highly effective method of contraception
-Participants must not have predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis
-Participants must not have a history of drug-induced psoriasis
-Participants must not have used tanning booths for at least 4 weeks before baseline
-Participants must not have previous use of guselkusemab
-Participants must not have previously participated in any other study with ixekizumab, or any other IL-17 or IL-23 antagonists, or have received treatment with other IL-17 or IL-23 antagonists
-Participants must not have a known allergy or hypersensitivity to any biologic therapy